GeoVax to Showcase COVID-19 Vaccine and Cancer Therapy Research at Roth Conference

Biotechnology company GeoVax Labs is set to provide insights into its advanced clinical research during the upcoming 37th Annual Roth Conference in Dana Point, California. Chairman and CEO David Dodd will participate in a fireside chat, offering investors and industry professionals a comprehensive overview of the company's promising vaccine and therapeutic developments.

The presentation will focus on two primary research areas: a novel COVID-19 vaccine candidate and an innovative oncological gene-directed therapy. GeoVax's lead COVID-19 vaccine, GEO-CM04S1, is currently undergoing multiple Phase 2 clinical trials targeting diverse patient populations, including immunocompromised individuals and patients with chronic lymphocytic leukemia.

The company recently secured a significant BARDA-funded contract to conduct a 10,000-participant Phase 2b clinical trial comparing GEO-CM04S1 against existing authorized COVID-19 vaccines. This research aims to address limitations in current vaccine technologies, particularly for patients with compromised immune systems.

In the oncology sector, GeoVax is advancing Gedeptin®, a promising gene-directed therapy for solid tumors. The company has completed a multicenter Phase 1/2 clinical trial focusing on advanced head and neck cancers and plans to initiate a Phase 2 trial combining Gedeptin® with an immune checkpoint inhibitor.

These developments underscore GeoVax's commitment to developing innovative medical solutions for complex health challenges. By targeting both infectious diseases and cancer, the company demonstrates a comprehensive approach to addressing critical medical needs through advanced biotechnology research.

The Roth Conference presentation represents an important opportunity for GeoVax to communicate its scientific progress and potential breakthrough treatments to investors, medical professionals, and the broader scientific community.